Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057712 | 0.90 | ALDH1A1 (0.43) | SMN1; SMN2 | |
| SCHEMBL2932687 | 0.89 | P2RY14 (0.60) | P2RY14MRGPRX4LTB4RLTB4R2RXRA | |
| SCHEMBL13057709 | 0.87 | P2RY14 (0.53) | P2RY14MRGPRX4LTB4RLTB4R2SLC22A12 | |
| SCHEMBL13057677 | 0.85 | TSHR (0.50) | P2RY14MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL2933945 | 0.84 | RECQL (0.45) | P2RY14MRGPRX4LTB4RLTB4R2 | |
| SCHEMBL2934240 | 0.81 | P2RY14 (0.65) | P2RY14MRGPRX4SMN1; SMN2LTB4RLTB4R2 | |
| SCHEMBL2927190 | 0.80 | P2RY14 (0.64) | P2RY14MRGPRX4LTB4RLTB4R2 | |
| SCHEMBL13807483 | 0.79 | P2RY14 (0.48) | P2RY14MRGPRX4LTB4RLTB4R2 | |
| SCHEMBL13057710 | 0.79 | ALDH1A1 (0.46) | — | |
| SCHEMBL2932632 | 0.78 | P2RY14 (0.64) | P2RY14MRGPRX4SMN1; SMN2LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR52, GPR35 | P2RY14 423/4885MRGPRX4 390/4885TP53 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.